Insider trades
RA Capital Nexus Fund II, Director of Climb Bio CLYM, has filed 40 purchases and 2 sales on the open market. Over the past 12 months that comes to a net purchase of $53M. The latest trade was on 09/28.
RA Capital Nexus Fund II
Director
- Company
- Climb Bio CLYM
- First filing
- 23/03/30
- Trades
- 122 trades
- Buys / sales
- 40 / 2
- 12-month net buying
- $53M
- Last trade
- 09/28
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
COAG | Open-market buy | 05/04–05/06 | 05/06 | 2,840,429 sh6 trades | $18.39avg. | $52,222,945.65 | +81.8% |
Climb BioCLYM | Open-market buy | 01/05 | 01/07 | 7,111 sh | $3.50 | $24,888.5 | +0.2% |
CLYM | Open-market buy | 25/12/11–25/12/12 | 25/12/15 | 314,561 sh2 trades | $2.40avg. | $754,737.14 | +10.2% |
PepGenPEPG | Open-market buy | 25/09/26 | 25/09/30 | 9,375,000 sh | $3.20 | $30,000,000 | +102.1% |
HOWL | Open-market buy | 25/05/12–25/05/14 | 25/05/14 | 536,426 sh3 trades | $0.91avg. | $487,187.92 | +9.4% |
JANX | Open-market buy | 25/03/05–25/03/07 | 25/03/07 | 824,041 sh4 trades | $30.75avg. | $25,342,964.88 | +8.8% |
| Open-market buy | 24/10/18 | 24/10/22 | 1,200,000 sh | $44.75 | $53,700,000 | +14.8% | |
ANTX | Open-market sale | 24/08/09 | 24/08/13 | 3,525,094 sh2 trades | $1.08avg. | $3,807,101.52 | −92.1% |
CLYM | Open-market buy | 24/06/27 | 24/07/01 | 13,008,546 sh2 trades | $3.84avg. | $49,952,816.64 | No record |
BOLD | Open-market buy | 24/04/02 | 24/04/04 | 312,500 sh2 trades | $16.00avg. | $5,000,000 | No record |
SPRY | Open-market buy | 24/03/25–24/03/27 | 24/03/27 | 1,401,299 sh3 trades | $9.48avg. | $13,289,410.41 | +16.4% |
LENZ | Open-market buy | 24/03/21 | 24/03/25 | 998,009 sh2 trades | $15.03avg. | $15,000,075.27 | No record |
PepGenPEPG | Open-market buy | 24/02/09 | 24/02/13 | 2,557,593 sh | $10.64 | $27,212,789.52 | +38.6% |
SPRY | Open-market buy | 23/09/21 | 23/09/25 | 2,700,000 sh2 trades | $3.03avg. | $8,183,525.74 | +46.1% |
| Open-market buy | 23/08/29 | 23/08/31 | 3,750,000 sh | $6.20 | $23,250,000 | +178.0% | |
AN2 TherapeuticsANTX | Open-market buy | 23/08/18 | 23/08/22 | 1,777,778 sh | $9.00 | $16,000,002 | +52.9% |
| Open-market buy | 23/07/21 | 23/07/25 | 5,161,290 sh | $7.75 | $39,999,997.5 | +65.5% | |
| Open-market buy | 23/07/19 | 23/07/21 | 495,008 sh | $12.46 | $6,167,799.68 | +6.5% | |
| Open-market buy | 23/03/28–23/03/30 | 23/03/30 | 509,145 sh3 trades | $29.07avg. | $14,798,692.96 | +7.8% | |
| Open-market buy | 23/03/23–23/03/27 | 23/03/27 | 498,556 sh3 trades | $26.99avg. | $13,457,372.44 | +8.2% |
